Repro-Med Systems, Inc. ( (KRMD) ) has released its Q3 earnings. Here is a breakdown of the information Repro-Med Systems, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
KORU Medical Systems, Inc., a prominent player in the medical technology sector, specializes in developing, manufacturing, and commercializing large volume subcutaneous infusion solutions aimed at enhancing patient care globally.
In its latest earnings report, KORU Medical Systems announced a significant 27% increase in third-quarter revenue, reaching $10.4 million. The company also raised its revenue guidance for 2025, reflecting its strong financial performance and strategic growth initiatives.
Key financial highlights include a 30% increase in core business revenues and a 21% rise in gross profit, despite a reported net loss of $0.8 million, which marks a 51% improvement over the previous year. The company also achieved a positive adjusted EBITDA of $0.09 million and maintained a healthy cash balance of $8.5 million. Strategic collaborations in Pharma Services and Clinical Trials were also announced, expanding KORU’s reach to new patient populations.
Looking ahead, KORU Medical Systems remains focused on accelerating revenue growth, advancing its innovation pipeline, and expanding its international presence. The company aims to leverage new pharmaceutical collaborations to treat more patients worldwide using its Freedom system.
With a positive outlook for the remainder of 2025, KORU Medical Systems is poised to continue its trajectory of growth and innovation in the medical technology sector.